We are studying the effects of disitamab vedotin alone or with pembrolizumab in patients with HER2-positive urothelial cancer. This trial aims to see if these treatments can improve outcomes for those with advanced disease.
This study is for participants from the previous SPRING trial to assess ongoing effects and safety of the treatment. We aim to gather more information on its long-term benefits.
We are testing a new treatment, ACI-24.060, to see if it is safe and can help generate an immune response in people with early Alzheimer's and adults with Down syndrome. This study will also look at its effects on brain amyloid levels.
We are studying whether alpelisib can improve adaptive behavior and overall health in children and adults with MCAP. The trial will also assess the safety and effects of the treatment on brain and spinal cord health.
We are studying whether imlifidase can help children with high sensitization receive a kidney transplant by improving compatibility with the donor. This trial will also look at kidney function and overall safety of the treatment.
We are investigating whether different doses of CSL300 can help reduce inflammation in adults with end-stage kidney disease undergoing dialysis. This study aims to understand its potential effects on heart health.
We are testing different doses of SAR443122 in adults with moderate to severe ulcerative colitis to see how well it works and its safety. The study will also look at improvements in symptoms and quality of life.
We are testing a new vaccine to see if it is safe and can help improve symptoms in people with early-stage Parkinson's disease. The study will also look at how the vaccine affects certain biological markers related to the disease.
We are studying a new therapy using cell-derived vesicles to see if it can help prevent lung problems in extremely preterm newborns. This trial will assess both safety and effectiveness compared to a placebo.
We are studying whether a new treatment called CPX-351 can help patients with specific types of acute myeloid leukemia achieve better remission compared to standard chemotherapy. This trial focuses on patients with de novo intermediate or adverse risk AML.
We are studying if replacing standard medications with belatacept helps kidney transplant patients with early graft dysfunction. The goal is to see if this approach improves kidney function and reduces rejection risks.
We are studying a combination of venetoclax and epcoritamab in patients with relapsed or refractory CLL or SLL. The goal is to see if this treatment improves disease control and overall survival compared to existing options.
We are studying whether a nasal spray can help stop episodes of a fast heart rate in children aged 6 to 17. The trial also looks at how safe the spray is for these young patients.
We are studying whether etrasimod can help adolescents aged 12 to 17 with moderately to severely active ulcerative colitis achieve remission. The trial will also look at the safety and how the body processes the medication.
We are studying whether the medication Dabigatran helps patients with blood clots in the heart after a heart attack recover better than a traditional treatment. This trial looks at how well each treatment resolves the clot and prevents complications.
We are studying a new treatment combining tolinapant with oral decitabine/cedazuridine for patients with relapsed or refractory peripheral T-cell lymphoma. The goal is to assess safety and effectiveness compared to the current standard treatment.
We are studying whether a combination of metformin and a structured lifestyle program can help older adults at risk for dementia improve their cognitive abilities and overall health compared to a self-guided approach.
We are investigating a new PET imaging method to measure HER2 status in patients with low HER2 breast cancer. This study aims to see if it can help better identify tumor characteristics and improve treatment planning.
We are comparing two treatment plans for newly diagnosed low-risk multiple myeloma patients to see which is more effective in reducing cancer cells. This study aims to understand the best approach for long-term patient health.
We are studying whether Oral Azacitidine, combined with best supportive care, is more effective than a placebo for patients with low- or intermediate-risk MDS. The goal is to see if it improves blood counts and reduces the need for blood transfusions.